BioCryst Pharmaceuticals
BCRX
#4836
Rank
โ‚ฌ1.85 B
Marketcap
7,26ย โ‚ฌ
Share price
0.62%
Change (1 day)
16.28%
Change (1 year)

EPS for BioCryst Pharmaceuticals (BCRX)

EPS in 2026 (TTM): -1,26ย โ‚ฌ

According to BioCryst Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -1,28ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of 1,11ย โ‚ฌ an increase over its 2024 EPS that were of -0,38ย โ‚ฌ.

EPS history for BioCryst Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-1,26ย โ‚ฌ-213.11%
20251,11ย โ‚ฌ-390.7%
2024-0,38ย โ‚ฌ-63.56%
2023-1,05ย โ‚ฌ-11.28%
2022-1,18ย โ‚ฌ29.13%
2021-0,91ย โ‚ฌ-4.63%
2020-0,96ย โ‚ฌ10.2%
2019-0,87ย โ‚ฌ0%
2018-0,87ย โ‚ฌ25.64%
2017-0,69ย โ‚ฌ4%
2016-0,67ย โ‚ฌ27.12%
2015-0,52ย โ‚ฌ-13.24%
2014-0,60ย โ‚ฌ23.64%
2013-0,49ย โ‚ฌ-30.38%
2012-0,70ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Gilead Sciences
GILD
-2,31ย โ‚ฌ 80.56%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
2,84ย โ‚ฌ-322.06%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
-2,34ย โ‚ฌ 82.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
0,67ย โ‚ฌ-152.08%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
-1,35ย โ‚ฌ 5.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
-3,86ย โ‚ฌ 202.08%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
-0,39ย โ‚ฌ-69.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
-2,82ย โ‚ฌ 120.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
-3,06ย โ‚ฌ 138.89%๐Ÿ‡บ๐Ÿ‡ธ USA